



October 27, 2022

PRIVATE AND CONFIDENTIAL

To:
The Board of Directors
LEPU ScienTech Medical Technology (Shanghai) Co., Ltd.*
樂普心泰醫療科技(上海)股份有限公司
1/F, 5/F
Building 41
No. 258, Xinzhuan Road
Songjiang District
Shanghai
PRC

Dear Sirs,

Re: Consent to the Issue of the Prospectus of LEPU ScienTech Medical Technology (Shanghai) Co., Ltd.* (樂普心泰醫療科技(上海)股份有限公司) (the "Company") in connection with the Global Offering (as defined below)

We, China International Capital Corporation Hong Kong Securities Limited, being the sole sponsor in connection with the global offering of the H shares of the Company (the "**Global Offering**") and the proposed listing of its shares on the Main Board of The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**"), refer to the prospectus of the Company dated October 27, 2022 (the "**Prospectus**").

We hereby give, and confirm that we have not withdrawn, our consent to the issue of the Prospectus in connection with the Global Offering with the inclusion therein of our opinions, and all references thereto and to our name and qualifications in the form and context in which they respectively appear in the Prospectus.

We also consent to a copy of this letter being (i) released to the Registrar of Companies in Hong Kong and the Stock Exchange and referred to it in the Prospectus, and (ii) made available for public inspection as described in the section headed "Documents Delivered to the Registrar of Companies and Available on Display" in Appendix VIII to the Prospectus.

Yours faithfully,

** For identification purpose only*

For and on behalf of

China International Capital Corporation Hong Kong Securities Limited

A handwritten signature in black ink, appearing to read 'Lily Li', is positioned above a horizontal line.

Name: Li Li

Position: Executive Director



羅兵咸永道

The Directors
LEPU ScienTech Medical Technology (Shanghai) Co., Ltd.*
樂普心泰醫療科技(上海)股份有限公司
Room 201
Building 41
No. 258, Xinzhuan Road
Songjiang District
Shanghai
PRC

** For identification purposes only*

27 October 2022

Dear Sirs,

We refer to the prospectus dated 27 October 2022 in connection with the proposed initial listing of the H shares of LEPU ScienTech Medical Technology (Shanghai) Co., Ltd.* 樂普心泰醫療科技(上海)股份有限公司 (the “Company”) on the Main Board of The Stock Exchange of Hong Kong Limited (the “Prospectus”), a copy of which is attached and initialled by us on its front cover for the purpose of identification.

Our engagement to prepare this letter has been performed in accordance with Hong Kong Standard on Investment Circular Reporting Engagements 200, *Accountants’ Reports on Historical Financial Information in Investment Circulars* issued by the Hong Kong Institute of Certified Public Accountants.

We hereby consent to the inclusion of our accountant’s report and our report on unaudited pro forma financial information, both dated 27 October 2022, in the Prospectus, and the references to our name in the form and context in which they are included.

Yours faithfully,



PricewaterhouseCoopers
Certified Public Accountants
Hong Kong



仲量聯行

Jones Lang LaSalle Corporate Appraisal and Advisory Limited
7/F One Taikoo Place
979 King's Road Hong Kong
tel +852 2846 5000 fax +852 2169 6001
Company Licence No.: C-030171

仲量聯行企業評估及諮詢有限公司
香港英皇道979號太古坊一座7樓
電話 +852 2846 5000 傳真 +852 2169 6001
公司牌照號碼: C-030171

LEPU ScienTech Medical Technology (Shanghai) Co., Ltd.*
樂普心泰醫療科技(上海)股份有限公司

1/F, 5/F
Building 41
No. 258, Xinzhuan Road
Songjiang District
Shanghai
PRC
Attention: The Board of Directors

October 27, 2022

Dear Sirs,

Consent to the Issue of the Prospectus of the Company in connection with the Global Offering and Proposed Listing

We refer to the prospectus of the Company dated October 27, 2022 (the “**Prospectus**”). We are the Independent Property Valuer to LEPU ScienTech Medical Technology (Shanghai) Co., Ltd.* (樂普心泰醫療科技(上海)股份有限公司) (the “**Company**”) in respect of the global offering and proposed listing of the H Shares of the Company on the Main Board of The Stock Exchange of Hong Kong Limited. Unless otherwise defined, capitalized terms used herein shall have the same meanings as those defined in the Prospectus.

We hereby give our consent, and confirm that we have not withdrawn our consent to the issue of the Prospectus with the inclusion therein of all reference to our name, statements, and opinions as set out in the Prospectus in the form and context in which they are respectively issued and or included or appear in the Prospectus.

We hereby consent to you releasing this letter to the Registrar of Companies in Hong Kong and The Stock Exchange of Hong Kong Limited and referring to it in the Prospectus. We also hereby consent to this letter and our property valuation report dated October 27, 2022 and copies thereof being made available on display as disclosed in the section headed “Documents Delivered to the Registrar of Companies and Available on Display” in Appendix VIII to the Prospectus.

[Signature page to follow]

** For identification purposes only*



Yours faithfully,

For and on behalf of
Jones Lang LaSalle Corporate Appraisal and Advisory Limited

A handwritten signature in black ink, appearing to read "Eddie T.W. Yiu", is written over a horizontal line.

Eddie T.W. Yiu
MHKIS, MRICS, RPS (GP)
Senior Director

Expert's consent

Date: October 27, 2022

To: **LEPU ScienTech Medical Technology (Shanghai) Co., Ltd.***
樂普心泰醫療科技(上海)股份有限公司 (the "Company")
1/F, 5/F
Building 41
No. 258, Xinzhuan Road
Songjiang District
Shanghai
PRC

Attn.: The Board of Directors

Dear Sirs,

Consent to the issue of the prospectus of the Company in connection with the proposed listing and global offering of the H shares of the Company

We refer to the prospectus of the Company dated October 27, 2022 (the "**Prospectus**") in connection with the global offering of its H shares and listing of the same on the Main Board of The Stock Exchange of Hong Kong Limited (the "**Listing**"). Unless otherwise defined, capitalized terms used herein shall have the same meanings as those defined in the Prospectus.

We hereby give our consent, and confirm that we have not withdrawn our consent, to the issue of the Prospectus with the inclusion therein of our legal opinions and all references to our name and qualifications in the form and context in which they appear in the Prospectus.

We also hereby consent to (a) our legal opinions and copies of this letter being made available on display as described in "Documents Delivered to the Registrar of Companies and Available on Display" in Appendix VIII to the Prospectus, and (b) this letter being released to the Registrar of Companies in Hong Kong and the Stock Exchange and referring to it in the Prospectus.

海问律师事务所 HAIWEN & PARTNERS

北京市海问律师事务所

地址: 北京市朝阳区东三环中路5号财富金融中心20层(邮编100020)

Address: 20/F, Fortune Financial Center, 5 Dong San Huan Central Road, Chaoyang District, Beijing 100020, China
电话(Tel): (+86 10) 8560 6888 传真(Fax): (+86 10) 8560 6999 www.haiwen-law.com

北京 BEIJING | 上海 SHANGHAI | 深圳 SHENZHEN | 香港 HONG KONG | 成都 CHENGDU

** For identification purposes only*

Yours faithfully,

***For and on behalf of
Haiwen & Partners***

A handwritten signature in black ink, consisting of a series of connected loops and a final horizontal stroke.

Name: Wei Shuangjuan

Position: Partner

LEPU ScienTech Medical Technology (Shanghai) Co., Ltd.*

樂普心泰醫療科技(上海)股份有限公司

1/F, 5/F

Building 41

No. 258, Xinzhuan Road

Songjiang District

Shanghai

PRC

Attention: The Board of Directors

October 27, 2022

Dear Sirs,

Consent to the Issue of the Prospectus of the Company in connection with the Global Offering and Proposed Listing of the H shares of the Company

We refer to the prospectus of the Company dated October 27, 2022 (the “**Prospectus**”). We are the industry consultant to LEPU ScienTech Medical Technology (Shanghai) Co., Ltd.* (樂普心泰醫療科技(上海)股份有限公司) (the “**Company**”) in respect of the global offering and proposed listing of the H Shares of the Company on the Main Board of The Stock Exchange of Hong Kong Limited. Unless otherwise defined, capitalized terms used herein shall have the same meanings as those defined in the Prospectus.

We hereby give, and confirm we have not withdrawn, our consent to the issue of the Prospectus, with the inclusion therein of all reference to our name, statements, opinions and reports as set out in the Prospectus in the form and context in which they are respectively issued and or included or appear in the Prospectus.


We hereby consent to you releasing this letter to the Registrar of Companies in Hong Kong and The Stock Exchange of Hong Kong Limited and referring to it in the Prospectus. We also consent to this letter and our industry report dated October 27, 2022 and copies thereof being made available on display as disclosed in the section headed “Documents Delivered to the Registrar of Companies and Available on Display” in Appendix VIII to the Prospectus.

[Signature page to follow]

* For identification purposes only

Yours faithfully,

For and on behalf of
Frost & Sullivan (Beijing) Inc., Shanghai Branch Co.



Name: Charles Lau
Title: Consulting Director

Date: October 27, 2022

Our ref 2292485

LEPU ScienTech Medical Technology (Shanghai) Co., Ltd.*

樂普心泰醫療科技(上海)股份有限公司

1/F, 5/F

Building 41

No. 258, Xinzhuan Road

Songjiang District

Shanghai

PRC

Attention: The Board of Directors

Dear Sirs,

Consent to the Issue of the Prospectus of the Company in connection with the Global Offering and Proposed Listing

We refer to the prospectus of the Company dated October 27, 2022 (the "Prospectus"). We are the International Sanctions Legal Advisors to LEPU ScienTech Medical Technology (Shanghai) Co., Ltd.* (樂普心泰醫療科技(上海)股份有限公司) (the "Company") in respect of the global offering and proposed listing of the H Shares of the Company on the Main Board of The Stock Exchange of Hong Kong Limited. Unless otherwise defined, capitalized terms used herein shall have the same meanings as those defined in the Prospectus.

We hereby give our consent, and confirm that we have not withdrawn our consent to the issue of the Prospectus with the inclusion therein of my name, statements, and extracts of advice as set out in the Prospectus in the form and context in which they are respectively issued and or included or appear in the Prospectus.

We hereby consent to you releasing this letter to the Registrar of Companies in Hong Kong and The Stock Exchange of Hong Kong Limited and referring to it in the Prospectus. We also hereby consent to this letter and my legal memorandum dated October 27, 2022 and copies thereof being made available on display as disclosed in the section headed "Documents

Partners
T C Hill
M Lin
O Chan
D Y C So
C J Dobby
M D R Parsons
N W O Tang
E J Low
J P Kwan
S K S Li
L H S Leung
A J McGinty
L Davidson
A Croke
J E M Leitch
B A Phillips

Counsel
A D E Cobden
K K S Wong
K C W Lee
J S F Yim
J Leung
T Liu
D Lau
S Suen

Foreign Legal
Consultants
S Tang
(New York, USA)
B Kostrzewa
(District of Columbia,
USA)

*Notary Public

Hogan Lovells is an affiliated business of Hogan Lovells International LLP, a limited liability partnership registered in England and Wales.

Hogan Lovells is part of an international legal practice that includes Hogan Lovells International LLP, Hogan Lovells US LLP and their affiliated businesses, with offices in: Alicante Amsterdam Baltimore Beijing Birmingham Boston Brussels Colorado Springs Denver Dubai Dusseldorf Frankfurt Hamburg Hanoi Ho Chi Minh City Hong Kong Houston Johannesburg London Los Angeles Luxembourg Madrid Mexico City Miami Milan Minneapolis Monterrey Munich New York Northern Virginia Paris Perth Philadelphia Rome San Francisco São Paulo Shanghai Silicon Valley Singapore Sydney Tokyo Warsaw Washington, D.C. Associated Offices: Budapest Jakarta Riyadh Shanghai FTZ Ulaanbaatar. Business Services Centers: Johannesburg Louisville. Legal Services Center: Berlin.

The word "partner" is used to describe a partner or member of Hogan Lovells International LLP, Hogan Lovells US LLP or any of their affiliated entities or any employee or consultant with equivalent standing. Certain individuals, who are designated as partners, but who are not members of Hogan Lovells International LLP, do not hold qualifications equivalent to members. For more information about Hogan Lovells, the partners and their qualifications, see www.hoganlovells.com.


Hogan Lovells is a member of the Pacific Rim Advisory Council with member offices in: Argentina Australia Brazil Canada Chile China (Mainland) Colombia France Hong Kong India Indonesia Japan Korea Malaysia Mexico Netherlands New Zealand Peru Philippines Singapore Taiwan Thailand USA Venezuela.

Delivered to the Registrar of Companies and Available on Display” in Appendix VIII to the Prospectus.

[Signature page to follow]

** For identification purposes only*

Yours faithfully,



Hogan Lovells